MAPT and Alzheimer disease: Molecular subtyping of AD corresponding to dysregulated pathways, including Aβ neuroinflammation, synaptic signaling, tau‐mediated neurodegeneration, mitochondria organization, immune activity, and myelination, have been widely investigated (Neff et al., 2021).